Evidence map›Paper›PMID 40899655›Full record

ArticleBioanalysis2025

Selective IgM digestion improves anti-AAV IgG detection in the immune complex assay format.

Uwe Wessels, Alexander Pöhler, Francesca Ros, Kay-Gunnar Stubenrauch

Abstract read
In one paragraph

Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Uwe WesselsRoche Pharma Research & Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Alexander PöhlerRoche Pharma Research & Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Francesca RosRoche Pharma Research & Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Kay-Gunnar StubenrauchRoche Pharma Research & Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo confirm the observation of IgM interference in the anti-adeno-associated virus (AAV) IgG immune complex (IC) assay format and to verify that IgM-specific digestion can improve anti-AAV IgG detection in IC assays.

methodsTreatment-emergent anti-AAV2 and anti-AAV9 IgG signals were measured in IC assays with and without IgM-specific digestion. Anti-AAV2 and anti-AAV9 IgM signals were measured in parallel.

resultsIgM digestion increased anti-AAV2 and anti-AAV9 IgG signals when anti-AAV2 or anti-AAV9 IgM were present in the matrix.

conclusionsCo-existing anti-AAV IgM cause interference in the anti-AAV IC assay format. Selective IgM digestion improves the detection of anti-AAV IgG in the IC assay.

Indexed as

Antibodies, ViralAntigen-Antibody ComplexImmunoglobulin GImmunoglobulin MHumansImmunoassayAntibodies, ViralAntigen-Antibody ComplexImmunoglobulin GImmunoglobulin Mgene therapyIgM interferenceIgM proteaseImmune complex assaytotal anti-AAV antibody assay

Identifiers

PMID40899655
PMCPMC12416191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.